AMAG Pharmaceuticals Upgraded by Jefferies Group to “Hold” (AMAG)
AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded by stock analysts at Jefferies Group from an “underperform” rating to a “hold” rating in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $19.00 price objective on the stock, up from their previous price objective of $16.00. Jefferies Group’s price target would indicate a potential downside of 9.78% from the stock’s previous close.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.91% during mid-day trading on Thursday, hitting $21.06. 279,251 shares of the company’s stock traded hands. AMAG Pharmaceuticals has a 1-year low of $15.26 and a 1-year high of $28.42. The stock’s 50-day moving average is $23.35 and its 200-day moving average is $23.50. The company’s market cap is $457.8 million.
In other AMAG Pharmaceuticals news, Insider Christopher White sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $22.37, for a total transaction of $89,480.00. Following the sale, the insider now directly owns 24,834 shares of the company’s stock, valued at approximately $555,537. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Other equities research analysts have also recently issued reports about the stock. Analysts at Ladenburg Thalmann downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. They noted that the move was a valuation call. Analysts at Zacks downgraded shares of AMAG Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, December 24th. They now have a $29.40 price target on the stock. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $24.40.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.